Literature DB >> 3405984

Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma.

G C Roush1, J J Nordlund, B Forget, S B Gruber, J M Kirkwood.   

Abstract

In the determination of risk for melanoma, relatively little is known about the possible independence of two important predictors, total nevi and clinically dysplastic nevi. From a study conducted in Sydney, Australia [see J. J. Nordlund et al., Cancer Res. 45, 1855-1861 (1985)], 246 cases of melanoma (excluding 7% of targeted patients with a history of melanoma in a first-degree relative) were compared with 134 nonmelanoma controls. Participants had been examined by a dermatologist and an oncologist. Logistic regression analysis was used and included an age-sex interaction term in computing all estimates of relative risk in this report. Relative risk for melanoma in those with 16+ total nevi was significantly elevated at 1.8 but declined to a statistically nonsignificant level of 1.2 (95% confidence limit (CL): 0.7, 2.0) after adjustment for dysplastic nevi. In contrast, relative risk for melanoma in those with any dysplastic nevi was 7.6 (95% CL: 3.6, 16.0) but was maintained at a similarly elevated and statistically significant level of 7.7 (95% CL: 3.5, 17.1) after adjustment for total nevi. These patterns were even more evident in the younger half of the study population. The analyses suggest that much of the association between TN and nonfamilial melanoma is explained by the presence of dysplastic nevi and, conversely, they imply that dysplastic nevi represent a clinically distinct, qualitative disorder rather than simply a quantitative disorder wherein dysplastic nevi stem merely from an increase in total nevi. The dysplastic nevus syndrome accounts for 32% of all nonfamilial melanomas.

Entities:  

Mesh:

Year:  1988        PMID: 3405984     DOI: 10.1016/0091-7435(88)90003-5

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  8 in total

1.  DNA repair synthesis following irradiation with 254-nm and 312-nm ultraviolet light is not diminished in fibroblasts from patients with dysplastic nevus syndrome.

Authors:  H W Thielmann; O Popanda; L Edler; A Böing; E G Jung
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Self screening for risk of melanoma: validity of self mole counting by patients in a single general practice.

Authors:  P Little; M Keefe; J White
Journal:  BMJ       Date:  1995-04-08

3.  Malignant melanoma risk by nativity, place of residence at diagnosis, and age at migration.

Authors:  T M Mack; B Floderus
Journal:  Cancer Causes Control       Date:  1991-11       Impact factor: 2.506

Review 4.  Familial melanoma: a complex disorder leading to controversy on DNA testing.

Authors:  Femke A de Snoo; Wilma Bergman; Nelleke A Gruis
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

5.  A local education campaign on early diagnosis of malignant melanoma.

Authors:  K Hoffmann; T Dirschka; H Schatz; M Segerling; T Tiemann; A Hoffmann; P Altmeyer
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

6.  Fibroblasts derived from patients with dysplastic nevus syndrome are not more sensitive towards 254-nm and 312-nm ultraviolet light than fibroblasts from normal donors.

Authors:  H W Thielmann; L Edler; A Brucker; E G Jung
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI.

Authors:  G C Roush; R L Barnhill; M S Ernstoff; J M Kirkwood
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

Review 8.  Current Data on Risk Factor Estimates Does Not Explain the Difference in Rates of Melanoma between Hispanics and Non-Hispanic Whites.

Authors:  Sonia Kamath; Kimberly A Miller; Myles G Cockburn
Journal:  J Skin Cancer       Date:  2016-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.